Transforming medicine

Acacia Pharma Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US

Results of Annual General Meeting

Acacia Pharma to Participate in Jefferies Virtual Healthcare Conference

Acacia Pharma Appoints Debra Hussain as Chief Commercial Officer

Acacia Pharma benoemt Debra Hussain tot Chief Commercial Officer

Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

Acacia Pharma meldt vervroegde terugbetaling van lening van Hercules Technology Growth Capital

Acacia Pharma Becomes New Industry Supporter of the American Society of Anesthesiologists

Acacia Pharma wordt nieuwe Industry Supporter van de  American Society of Anesthesiologists

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

Results for the Year ended 31 December 2020

Resultaten van het boekjaar eindigend op 31 december 2020

Acacia Pharma publiceert op 29 maart 2021 de jaarresultaten 2020 en geeft daarbij een ‘business update'

Proposed Capital Raising

Acacia Pharma Group plc - Results of Placing - EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities

Acacia Pharma Group plc - Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS®

Wijziging van EU-lidstaat van herkomst

Change of EU Home Member State

Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

Acacia Pharma brengt BYFAVO™ op de markt in de Verenigde Staten voor procedurele sedatie bij volwassenen die een medische ingreep ondergaan die 30 minuten of minder duurt

Acacia Pharma Wins BEL Small Company of the Year for the Second Consecutive Year

Acacia Pharma is voor het tweede opeenvolgende jaar uitgeroepen tot ‘BEL Small Company of the Year’